Compare SLNG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | CUE |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 233.5M |
| IPO Year | 2019 | 2017 |
| Metric | SLNG | CUE |
|---|---|---|
| Price | $5.28 | $31.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $120.00 |
| AVG Volume (30 Days) | 36.1K | ★ 345.6K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,245,000.00 | $27,466,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $3.21 | $0.17 |
| 52 Week High | $7.07 | $45.50 |
| Indicator | SLNG | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 52.87 |
| Support Level | $4.79 | $23.47 |
| Resistance Level | $5.46 | $33.11 |
| Average True Range (ATR) | 0.37 | 4.89 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 31.33 | 45.37 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. The company has a geographical presence in the United States and Mexico.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.